The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease

Blood Cells, Molecules, and Diseases

Volumn 47, Issue 4, 2011, Pages 235-242

  Ikuta, Tohru ^a   Adekile, Adekunle D ^b   Gutsaeva, Diana R ^a   Parkerson, James B ^a   Yerigenahally, Shobha D ^a   Clair, Betsy ^a   Kutlar, Abdullah ^a   Odo, Nadine ^a   Head, C Alvin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b KUWAIT UNIVERSITY   (Kuwait)

Author keywords

CAMP; Fetal hemoglobin; GM CSF; Leukocytosis; Sickle cell disease

Indexed keywords

CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOGLOBIN F; HYDROXYUREA; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; ATTENUATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFECT; ENZYME PHOSPHORYLATION; ERYTHROBLAST; ERYTHROID CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REDUCTION KINETICS; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; TREATMENT DURATION;

ANEMIA, SICKLE CELL; CELL LINE; CELLS, CULTURED; CYCLIC AMP; DOWN-REGULATION; ERYTHROID CELLS; FETAL HEMOGLOBIN; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYDROXYUREA; LEUKOCYTE COUNT; RETROSPECTIVE STUDIES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 82955236099     PISSN: 10799796     EISSN: 10960961     Source Type: Journal    
DOI: 10.1016/j.bcmd.2011.08.005     Document Type: Article

References (62)

1. Charache S., Barton F.B., Moore R.D., et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive switching agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 1996, 75:300-326.
2. Kaul D.K., Hebbel R.P. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J. Clin. Invest. 2000, 106:411-420.
3. Reiter C.D., Wang X., Tanus-Santos J.E., et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 2001, 8:1383-1389.
4. Miller B.A., Salameh M., Ahmed M., et al. High fetal hemoglobin production in sickle cell anemia in the eastern province of Saudi Arabia is genetically determined. Blood 1986, 67:1404-1410.
5. Craig J.E., Rochette J., Fisher C.A., et al. Dissecting the loci controlling fetal haemoglobin production on chromosomes 11p and 6q by the regressive approach. Nat. Genet. 1996, 12:58-64.
6. Close J., Game L., Clark B., et al. Genome annotation of a 1.5Mb region of human chromosome 6q23 encompassing a quantitative trait locus for fetal hemoglobin expression in adults. BMC Genomics 2004, 5:33-46.
7. Yavarian M., Karimi M., Bakker E., Harteveld C.L., Giordano P.C. Response to hydroxyurea treatment in Iranian transfusion-dependent ;-thalassemia patients. Haematologica 2004, 89:1172-1178.
8. Lettre G., Sankaran V.G., Bezerra M.A.C., et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and ;-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc. Natl. Acad. Sci. USA 2008, 105:11869-11874.
9. Boggs D.R., Hyde F., Srodes C. An unusual pattern of neutrophil kinetics in sickle cell anemia. Blood 1973, 41:59-65.
10. Platt O.S., Dover G.J. Sickle cell disease. Hematology of Infancy and Childhood 1992, 732-782. Saunders, Philadelphia. F.A. Oski (Ed.).
11. Miller S.T., Sleeper L.A., Pegelow C.H., et al. Prediction of adverse outcomes in children with sickle cell disease. N. Engl. J. Med. 2000, 342:83-89.
12. Charache S., Dover G.J., Moore R.D., et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992, 79:2555-2565.
13. Ware R.E., Eggleston B., Redding-Lallinger R., et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002, 99:10-14.
14. Croizat H. Circulating cytokines in sickle cell patients during steady state. Br. J. Haematol. 1994, 87:592-597.
15. Croizat H., Nagel R.L. Circulating cytokines response and the level of erythropoiesis in sickle cell anemia. Am. J. Hematol. 1999, 60:105-115.
16. Conran N., Saad S.T.O., Costa F.F., Ikuta T. Leukocyte numbers correlate with plasma levels of granulocyte-macrophage colony-stimulating factor in sickle cell disease. Ann. Hematol. 2007, 86:255-261.
17. Ikuta T., Ausenda S., Cappellini M.D. Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cyclic GMP-dependent protein kinase pathway. Proc. Natl. Acad. Sci. USA 2001, 98:1847-1852.
18. Kuroyanagi Y., Kaneko Y., Muta K., et al. cAMP differentially regulates g-globin gene expression in erythroleukemic cells and primary erythroblasts through c-Myb expression. Biochem. Biophys. Res. Commun. 2006, 344:1038-1047.
19. Bailey L., Kuroyanagi Y., Franco-Penteado C.F., et al. Expression of the -globin gene is sustained by the cAMP-dependent pathway in ;-thalassaemia. Br. J. Haematol. 2007, 138:382-395.
20. Miller B.A., Olivieri N., Salameh M., et al. Molecular analysis of the high-hemoglobin-F phenotype in Saudi Arabian sickle cell anemia. N. Engl. J. Med. 1987, 316:244-250.
21. Huisman T.H., Henson J.B., Wilson J.B. A new high-performance liquid chromatographic procedure to quantitate hemoglobin A1c and other minor hemoglobins in blood of normal, diabetic, and alcoholic individuals. J. Lab. Clin. Med. 1983, 102:163-173.
22. Uddin S., Ah-Kang J., Ulaszek J., Mahmud D., Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc. Natl. Acad. Sci. USA 2004, 101:147-152.
23. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 162:156-159.
24. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, Cold Spring Harbor Press, Cold Spring Harbor, NY.
25. Ikuta T., Kan Y.W. In vivo protein-DNA interactions at the beta-globin gene locus. Proc. Natl. Acad. Sci. USA 1991, 88:10188-10192.
26. Ikuta T., Kan Y.W., Swerdlow P.S., Faller D.V., Perrine S.P. Alterations in protein-DNA interactions in the -globin gene promoter in response to butyrate therapy. Blood 1998, 92:2924-2933.
27. Conran N., Oresco-Santos C., Acosta H.C., et al. Increased soluble guanylate cyclase activity in the red blood cells of sickle cell patients. Br. J. Haematol. 2004, 124:547-554.
28. Inoue A., Kuroyanagi Y., Terui K., Moi P., Ikuta T. Negative regulation of -globin gene expression by cAMP-dependent pathway in erythroid cells. Exp. Hematol. 2004, 32:244-253.
29. Kitamura T., Tange T., Terasawa T., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell. Physiol. 1989, 140:323-334.
30. Kitamura T., Tojo A., Kuwaki T., et al. Identification and analysis of human erythropoietin receptors on a factor-dependent cell line, TF-1. Blood 1989, 73:375-380.
31. Nagel R.L., Vichinsky E., Shah M., et al. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood 1993, 81:9-14.
32. Kase H., Iwahashi K., Nakanishi S., et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem. Biophys. Res. Commun. 1987, 142:436-440.
33. Yamamoto K.K., Gonzalez G.A., Biggs W.H., Montminy M.R. Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB. Nature 1988, 334:494-498.
34. Pace B.S., Qian X.H., Sangerman J., et al. p38 MAP kinase activation mediates gamma-globin gene induction in erythroid progenitors. Exp. Hematol. 2003, 31:1089-1096.
35. Bhanu N.V., Trice T.A., Lee Y.T., Miller J.L. A signaling mechanism for growth-related expression of fetal hemoglobin. Blood 2004, 103:1929-1933.
36. Ma Q., Wyszynski D.F., Farrell J.J., et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J. 2007, 7:386-394.
37. Cokic V.P., Smith R.D., Beleslin-Cokic B.B., et al. Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. J. Clin. Invest. 2003, 111:231-239.
38. Takahashi M., Kitagawa S., Masuyama J.-I., et al. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor. Circulation 1996, 93:1185-1193.
39. Perelman N., Selvaraj S.K., Batra S., et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003, 102:1506-1514.
40. Shannon M.F., Coles L.S., Vadas M.A., Cockerill P.N. Signals for activation of the GM-CSF promoter and enhancer in T cells. Crit. Rev. Immunol. 1997, 17:301-323.
41. Thorens B., Mermod J.J., Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell 1987, 48:671-679.
42. Bell A.L., Magill M.K., McKane W.R., Kirk F., Irvine A.E. Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol. Int. 1995, 14:177-182.
43. Xu J., Sankaran V.G., Ni M., et al. Transcriptional silencing of -globin by BCL11A involves long-range interactions and cooperation with SOX6. Genes Dev. 2010, 24:783-798.
44. Steinberg M.H. Drug therapy: management of sickle cell disease. N. Engl. J. Med. 1999, 340:1021-1030.
45. Papayannopoulou T., Torrealba de Ron A., Veith R., Knitter G., Stamatoyannopoulos G. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science 1984, 224:617-619.
46. Galanello R., Stamatoyannopoulos G., Papayannopoulou T. Mechanism of Hb F stimulation by S-stage compounds. In vitro studies with bone marrow cells exposed to 5-azacytidine, Ara-C, or hydroxyurea. J. Clin. Invest. 1988, 81:1209-1216.
47. Polson J.B., Strada S.J. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 1996, 36:403-427.
48. Jiang J., Jordan S.J., Barr D.P., et al. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol. Pharmacol. 1997, 52:1081-1086.
49. Sanders S.P., Kim J., Connolly K.R., et al. Nitric oxide inhibits rhinovirus-induced granulocyte macrophage colony-stimulating factor production in bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 2001, 24:317-325.
50. Huang J., Yakubu M., Kim-Shapiro D.B., King S.B. Rat liver-mediated metabolism of hydroxyurea to nitric oxide. Free Radic. Biol. Med. 2006, 40:1675-1681.
51. Blackshear P.J. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem. Soc. Trans. 2002, 30:945-952.
52. Stumpo D.J., Broxmeyer H.E., Ward T., et al. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood 2009, 114:2401-2410.
53. Blackshear P.J., Phillips R.S., Vazquez-Matias J., Mohrenweiser H. Polymorphisms in the genes encoding members of the tristetraprolin family of human tandem CCCH zinc finger proteins. Prog. Nucleic Acid Res Mol. Biol. 2003, 75:43-68.
54. Yarbro J.W. Mechanism of action of hydroxyurea. Semin. Oncol. 1992, 19:1-10.
55. Spitzer G., Adkins D., Mathews M., et al. Randomized comparison of G-CSF+GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy. Bone Marrow Transplant. 1997, 20:921-930.
56. Gabbianelli M., Pelosi E., Bassano E., et al. Granulocyte-macrophage colony-stimulating factor reactivates fetal hemoglobin synthesis in erythroblast clones from normal adults. Blood 1989, 74:2657-2667.
57. McDonagh K.T., Dover G.J., Donahue R.E., et al. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp. Hematol. 1992, 20:1156-1164.
58. Pieters R.C., Rojer R.A., Saleh A.W., Saleh A.E., Duits A.J. Molgramostim to treat SS-sickle cell leg ulcers. Lancet 1995, 345:528.
59. Abboud M., Laver J., Blau C.A. Granulocytosis causing sickle-cell crisis. Lancet 1998, 351:28.
60. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9years of treatment. JAMA 2003, 289:1645-1651.
61. Bakanay S.M., Dainer E., Clair B., et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 2005, 105:545-547.
62. Stephen T., Baiqing L., Stephen D., et al. Secretion of the eosinophil-active cytokines interleukin-5, granulocyte/macrophage colonystimulating factor and interleukin-3 by bronchoalveolar lavage CD4+ and CD8+ T cell lines in atopics asthmatics, and atopic and nonatopic controls. Eur. J. Immunol. 1995, 25:2727-2731.